Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials
07:00am, Wednesday, 22'nd Sep 2021
Summit Therapeutics Inc (NASDAQ: SMMT) announced that the FDA disagrees with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. In a regulatory filing, the Company said that t
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021
08:01am, Wednesday, 11'th Aug 2021
Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its
Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of Action Data Additionally include Potential Benefit for the Control of Antimicrobial Res
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?
09:46am, Wednesday, 19'th May 2021
Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pr
Summit Therapeutics (SMMT): 26.62% Increase Explanation
10:35pm, Monday, 17'th May 2021
The stock price of Summit Therapeutics Inc (NASDAQ: SMMT) increased by 26.62% today. This is why it The post Summit Therapeutics (SMMT): 26.62% Increase Explanation appeared first on Pulse 2.0.
These 2 Nasdaq Stock Winners Could Change the World
03:01pm, Monday, 17'th May 2021
Find out why investors are more excited than ever about these two businesses.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
08:00am, Monday, 17'th May 2021
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.
Summit Therapeutics Announces Closing of $75 Million Rights Offering
02:59pm, Wednesday, 12'th May 2021
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.
Summit Therapeutics: Whether It's A Go-Private Candidate
02:05pm, Tuesday, 11'th May 2021
CEO Robert R. Duggan continues to aggressively buy shares and expand his ownership of the company.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Tim
Summit Therapeutics Announces Commencement of Rights Offering
08:04am, Wednesday, 21'st Apr 2021
Summit Therapeutics Inc. (‘Summit' or the ‘Company')
Summit Therapeutics Announces Rights Offering
07:00am, Friday, 26'th Mar 2021
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the C
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
09:47am, Wednesday, 16'th Dec 2020
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
07:00am, Monday, 23'rd Nov 2020
Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')
Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')
